Report Detail

Pharma & Healthcare Coccidioidomycosis - Pipeline Review, H1 2019

  • RnM3199181
  • |
  • 27 March, 2019
  • |
  • Global
  • |
  • 54 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Coccidioidomycosis - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coccidioidomycosis - Pipeline Review, H1 2019, provides an overview of the Coccidioidomycosis (Infectious Disease) pipeline landscape.

Coccidioidomycosis, also called Valley fever, is an infection caused by the fungus Coccidioides. Symptoms include fever, cough, chest pain, chills, headache, fatigue and joint aches. Risk factors include weakened immune system, age, pregnancy, race and environmental exposure. Treatment includes antifungal medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coccidioidomycosis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Coccidioidomycosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coccidioidomycosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coccidioidomycosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Coccidioidomycosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Coccidioidomycosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Coccidioidomycosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Coccidioidomycosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Coccidioidomycosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Coccidioidomycosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Coccidioidomycosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Coccidioidomycosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Coccidioidomycosis - Overview

              Coccidioidomycosis - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Coccidioidomycosis - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Coccidioidomycosis - Companies Involved in Therapeutics Development

                                      Amplyx Pharmaceuticals Inc

                                        F2G Ltd

                                          Valley Fever Solutions Inc

                                            Viamet Pharmaceuticals Inc

                                              Coccidioidomycosis - Drug Profiles

                                                Amphotericin B sodium - Drug Profile

                                                  Product Description

                                                    Mechanism Of Action

                                                      R&D Progress

                                                        APX-001 - Drug Profile

                                                          Product Description

                                                            Mechanism Of Action

                                                              R&D Progress

                                                                coccidioidomycosis vaccine - Drug Profile

                                                                  Product Description

                                                                    Mechanism Of Action

                                                                      R&D Progress

                                                                        nikkomycin Z - Drug Profile

                                                                          Product Description

                                                                            Mechanism Of Action

                                                                              R&D Progress

                                                                                olorofim - Drug Profile

                                                                                  Product Description

                                                                                    Mechanism Of Action

                                                                                      R&D Progress

                                                                                        VT-1161 - Drug Profile

                                                                                          Product Description

                                                                                            Mechanism Of Action

                                                                                              R&D Progress

                                                                                                VT-1598 - Drug Profile

                                                                                                  Product Description

                                                                                                    Mechanism Of Action

                                                                                                      R&D Progress

                                                                                                        Coccidioidomycosis - Dormant Projects

                                                                                                          Coccidioidomycosis - Product Development Milestones

                                                                                                            Featured News & Press Releases

                                                                                                              Jun 07, 2018: Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host

                                                                                                                Jul 13, 2017: FDA Grants Fast Track Designation to VT-1598 for Treatment of Valley Fever

                                                                                                                  May 17, 2017: Viamet To Present Data on VT-1598 at The American Society for Microbiology's ASM Microbe 2017 Conference

                                                                                                                    Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

                                                                                                                      Sep 15, 2016: FDA Grants QIDP Designation to VT-1598 for Treatment of Valley Fever

                                                                                                                        Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections

                                                                                                                          May 25, 2016: Viamet Receives Orphan Drug Designation from the FDA for VT-1598 for the Treatment of Coccidioidomycosis

                                                                                                                            May 20, 2015: Viamet Announces NIH Grant for Compounds Directed at Valley Fever

                                                                                                                              Appendix

                                                                                                                                Methodology

                                                                                                                                  Coverage

                                                                                                                                    Secondary Research

                                                                                                                                      Primary Research

                                                                                                                                        Expert Panel Validation

                                                                                                                                          Contact Us

                                                                                                                                            Disclaimer

                                                                                                                                            Summary:
                                                                                                                                            Get latest Market Research Reports on Coccidioidomycosis. Industry analysis & Market Report on Coccidioidomycosis is a syndicated market report, published as Coccidioidomycosis - Pipeline Review, H1 2019. It is complete Research Study and Industry Analysis of Coccidioidomycosis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                            Last updated on

                                                                                                                                            REPORT YOU MIGHT BE INTERESTED

                                                                                                                                            Purchase this Report

                                                                                                                                            $2,000.00
                                                                                                                                            $4,000.00
                                                                                                                                            $6,000.00
                                                                                                                                            1,600.00
                                                                                                                                            3,200.00
                                                                                                                                            4,800.00
                                                                                                                                            1,868.00
                                                                                                                                            3,736.00
                                                                                                                                            5,604.00
                                                                                                                                            315,880.00
                                                                                                                                            631,760.00
                                                                                                                                            947,640.00
                                                                                                                                            166,860.00
                                                                                                                                            333,720.00
                                                                                                                                            500,580.00
                                                                                                                                            Credit card Logo

                                                                                                                                            Related Reports


                                                                                                                                            Reason to Buy

                                                                                                                                            Request for Sample of this report